Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 7/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23921136 | 0.88 | PNP (0.42) | PNPKDM1AIDO1TK1MAPT | |
| SCHEMBL23921073 | 0.82 | MEN1 (0.42) | POLBMAPTKMT2ARXFP1 | |
| SCHEMBL23920921 | 0.81 | PNP (0.44) | PNPKDM1AIDO1TK1MAPT | |
| SCHEMBL23921217 | 0.81 | PNP (0.35) | PNPPOLBMAPTKMT2ARXFP1 | |
| SCHEMBL23920830 | 0.81 | PNP (0.43) | PNPTK1POLBKMT2A | |
| SCHEMBL23921066 | 0.80 | XDH (0.46) | PNPKMT2A | |
| SCHEMBL23921225 | 0.79 | PNP (0.55) | PNP | |
| SCHEMBL23921116 | 0.78 | CYP3A4 (0.46) | PNPTK1MAPTKMT2A | |
| SCHEMBL25932075 | 0.78 | KDM4E (0.45) | PNPTK1MAPT | |
| SCHEMBL23920942 | 0.77 | PNP (0.50) | PNPTK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PRKAG3 | PNP 111/4885KDM1A 1545/4885IDO1 2576/4885 |
| US-20210317156-A1 | NEW POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PDE7A | PNP 106/4885KDM1A 1720/4885IDO1 2714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.